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ABSTRACT
Although a minority of asthma patients suffer from severe asthma, they represent a major clinical
challenge in terms of poor symptom control despite high-dose treatment, risk of exacerbations,
and side effects. Novel biological treatments may benefit patients with severe asthma, but are
expensive, and are only effective in appropriately targeted patients. In some patients, symptoms
are driven by other factors than asthma, and all patients with suspected severe asthma (‘difficult
asthma’) should undergo systematic assessment, in order to differentiate between true severe
asthma, and ‘difficult-to-treat’ patients, in whom poor control is related to factors such as poor
adherence or co-morbidities. The Nordic Consensus Statement on severe asthma was developed
by the Nordic Severe Asthma Network, consisting of members from Norway, Sweden, Finland,
Denmark, Iceland and Estonia, including representatives from the respective national respiratory
scientific societies with the aim to provide an overview and recommendations regarding the
diagnosis, systematic assessment and management of severe asthma. Furthermore, the
Consensus Statement proposes recommendations for the organization of severe asthma manage-
ment in primary, secondary, and tertiary care.
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Introduction
Although the majority of asthma patients have mild to
moderate disease, a proportion of asthma patients have
difficulty in achieving control on standard treatment or
require very high doses of treatment to maintain
asthma control, and risk of side effects [1,2]: In the
patients with severe asthma, control is not obtained
despite correction of comorbidities and correct use of
high doses of asthma medications. Patients with severe
asthma represent a major unmet need, as they experi-
ence frequent exacerbations, are hospitalized more
often, and utilize the majority of health care expenses
in asthma [3].
There are a number of potential causes of poor symp-
tom control in asthma [4], and systematic assessment is
important when differentiating between patients with
severe asthma, and patients with other causes of poor
asthma control, such as lack of adherence or co-morbid-
ities, termed ‘difficult-to-treat’ asthma.
A number of novel treatments for severe asthma are
under development, some of which have been
approved for clinical use: treatment with anti-IgE and
anti-IL5 monoclonal antibodies are effective in redu-
cing the risk of asthma exacerbations [5,6]. However,
as the biological treatments target very specific path-
ways in the immune system, they are only effective in
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specific phenotypes of severe asthma [7]. Accordingly,
phenotyping of severe asthma patients has become
increasingly important, in order to target novel treat-
ments tailored to the appropriate patient.
Systematic assessment and phenotyping of patients
with possible severe asthma requires a highly specia-
lized setting, to ensure an appropriate and effective
diagnostic work-up [8]. The Nordic Countries share
similar healthcare systems, as well as a similar demo-
graphy: Based on the reported prevalence rates of
severe asthma [9,10], approximately 33,000 patients
among the 22 million inhabitants of the Nordic coun-
tries can be estimated to suffer from severe asthma.
The Nordic Severe Asthma Network (NSAN) was
established under NORA, the Nordic Respiratory
Societies in 2016, and consists of severe asthma specia-
lists from Iceland, Norway, Sweden, Denmark, Finland,
and Estonia. The aim of the NSAN is to increase
awareness of severe asthma in the Nordic Countries,
as well as improving the standard of care by providing
guidelines on the management of severe asthma. The
present Nordic consensus statement on severe asthma
aims to provide pragmatic, clinically useful guidance
on how to approach the patients with possible severe
asthma; how to perform systematic assessment, how to
identify potential candidates for biological treatments,
and how to organize a severe asthma clinic.
The definition of severe asthma
The ERS/ATS guidelines on severe asthma published
in 2014 define severe asthma as ‘asthma which
requires treatment with high dose inhaled corticoster-
oids (ICS) plus a second controller or systemic CS,
which remains “uncontrolled” despite this therapy, or
to prevent it from becoming “uncontrolled”’ [1]. Hence,
this definition includes patients, who are well con-
trolled on high-dose therapy, but lose symptom con-
trol when down-titrated [1]. The definitions of high
dose ICS are summarized in Table 1. ‘Second con-
trollers’ include long-acting beta-2 agonist, leukotriene
antagonists, long-acting anti-cholinergics or
methylxantines.
However, before a diagnosis of severe asthma can
be made, patients need to undergo a systematic
assessment: The ERS/ATS guidelines state that in
patients with ‘difficult asthma’, (high dose ICS treat-
ment + a second controller), the diagnosis of asthma
should be confirmed, and comorbidities addressed,
before a diagnosis of severe asthma can be made
(Figure 1). Patients in whom poor asthma control is
related to other factors, such as poor adherence or co-
morbidities, are termed ‘difficult-to-treat asthma’ 1
(Figure 1).
Table 1. Definitions of high dose inhaled steroids (ICS)*.
Name Daily dose (μg)*
Budesonide ≥1600
Fluticasone dipropionate ≥1000
Mometasone furoate ≥800
Beclomethason dipropionate ≥2000 (DPI or CFC MDI)
Ciclesonide ≥320
Fluticasone furoate ≥184
Triamcinolone acetonide ≥2000
* According to the ERS/ATS guidelines on severe asthma [1].
Table 2. Co-morbidities in severe asthma: diagnosis and management.
Co-morbidity Prevalence Test Management
Rhinosinusitis/Nasal polyps 50% [61] SNOT-22 questionaire
CT of sinuses
Nasendoscopy (ENT assessment)
Nasal lavage
Nasal steroid spray/drops
Surgery
Allergic Rhinoconjuctivitis
(*Positive skin prick test to
aeroallergens)
70% [61]* History + skin prick test/specific IgE Nasal steroids
Antihistamines
Montelukast
COPD 20% [171] History incl smoking
DLCO/HRCT (emphysema)
Add LAMA
Add Roflumilast
Rehabilitation
Dysfunctional Breathing 19–52 [59,172]% History/Nijmegen questionaire Physioterapy – breathing retraining
VCD 32–50% [59,74]- Laryngoscopy Speech therapist
Anxiety/Depression 4–17% [9,17] HADS questionnaire Psychiatric assessment
Psychiatrist
Medical treatment
Psychotherapy
OSAS 31% [80] Screening with STOP-BANG
Polysomnography/respiratory polygraphy
Weight loss
CPAP
Obesity 37% [18] BMI Dietician
Gastro-esophageal Reflux 17–74% [18,22,61,173] 3 months of empiric PPI
24-hours pH monitoring
PPI
Lifestyle interventions
Bronchiectasis 25–40% [91,92] HRCT Physiotherapy, inhalation of hyperosmolar
agents, low-dose macrolides
ABPA 1–2% [96] Total IgE, IgE and IgG to aspergillus fumigatus,
B-eosinophils, HRCT
Prednisolone. Anti-fungal treatment.
OSAS: Obstructive Sleep Apnea Syndrome.
VCD: Vocal Chord Dysfunction.
ABPA: Allergic Bronchopulmonary Aspergillosis.
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Systematic assessment of severe asthma
[Systematic assessment of patients with severe asthma
has been proven effective in reducing the number of
exacerbations, as well as overall health care utilization
2,11]. The process may be conceptualized as three
overall steps (Figure 2): 1) confirming the diagnosis,
assessing the level of asthma control, and describing
the phenotype, 2) assessing potential treatment bar-
riers, for example inhalation technique and adherence,
and 3) assessing potential exposures, such as allergens
or occupational exposure, and co-morbidities that may
contribute to symptoms.
Step 1. Asthma diagnosis, asthma control, and
phenotype
a. Diagnosis of asthma
A diagnosis of asthma should be based on a combina-
tion of clinical symptoms and the objective demonstra-
tion of variable airflow limitation [1,12].
The presence of at least two of the following increases
the likelihood of asthma: wheeze, shortness of breath,
chest tightness or cough, which vary in intensity and
over time, and may be triggered by factors, such as viral
infections, allergens, and non-specific irritants (strong
smells, smoke). Isolated symptoms or atypical symp-
toms decrease the likelihood of asthma [13].
Variable airflow limitation is defined as either rever-
sibility to beta-2-agonist or steroids, peak flow varia-
tion, or airway hyperresponsiveness to triggers such as
exercise, methacholine, histamine, or mannitol.
The choice of test will depend on the local avail-
ability and preference of the clinician: Bronchial chal-
lenge tests (BCTs) with methacholine, histamine,
mannitol, exercise, and eucapnic voluntary hyperpnea
(EVH) have a higher sensitivity than the reversibility
test(s) and PEF variation, and may therefore be the
preferred initial test [14]. Importantly, it is often neces-
sary to perform more than one diagnostic test in order
to confirm the diagnosis objectively, and it may be
more effective to include a standard test panel in the
diagnostic work-up of severe asthma, for exampl a
combination of reversibility testing, PEF diary, and a
BCT [14].
In patients with an FEV1 < 70%, which prohibits
performing a bronchial challenge test, reversibility test-
ing with either beta2-agonists or prednisolone and PEF
monitoring are the only possible tests. Importantly,
patients with severe asthma may have fixed airflow
obstruction, which is not reversible. This does not
preclude a diagnosis of asthma.
The objective confirmation of an asthma diagnosis is
of particular importance in patients with difficult
asthma, to avoid overtreatment and side effects. A
recent study patients managed for severe asthma across
five asthma clinics in Denmark, only approximately
Difficult asthma
(High dose ICS + 2. controllers or 
OCS > 50% during the last 12 months) 
Difficult-to-treat
asthma
Severe asthma
Systematic
assessment*
*Including a minimum of three months of specialist management
Poor control related to: 
• Poor adherence/ inhalation 
technique
• Exposure to 
allergens/irritants
• Co-morbidities
Poor control despite
• Good adherence/inhalation 
technique
• Management of expo-
sures and co-morbiditites
Figure 1. Severe asthma: definition and systematic assessement.
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50% had their diagnosis confirmed by an objective test,
despite having been managed by an asthma specialist
for a minimum of 2 years [15].
It is important to note that it is not always possible
to verify the diagnosis objectively, but in patients with-
out variable airflow obstruction, down-titration of the
dose of ICS followed by retesting should be considered.
b. Differential diagnoses
A number of conditions may mimic asthma (Box 1)
[1]. These differential diagnoses should be kept in
mind when assessing difficult asthma, and the diagnos-
tic work-up performed accordingly. On the other hand,
co-morbidities are important contributors to asthma
symptoms. Their prevalence and management are
described in the sections below.
c. Asthma control
The level of asthma control should be routinely
assessed, using definitions proposed by the ERS/ATS
guidelines on severe asthma: Regarding the level of
asthma control, the ERS/ATS guidelines define uncon-
trolled severe asthma as the presence of at least one of
the following four criteria:
(1) Poor symptom control, i.e. Asthma Control
Questionnaire (ACQ) consistently > 1.5 or
Asthma Control Test (ACT) < 20 (or not well
controlled as defined by The Global Initiative
for Asthma (GINA) over 3 months of
evaluation).
(2) Frequent severe exacerbations, defined as need-
ing two or more bursts of systemic corticoster-
oids (>3 days each) during the previous year.
Box 1. Differential diagnoses in severe asthma*.
● COPD
● Bronchiectasis
● Sarcoidosis
● Bronchiolitis obliterans
● Cystic Fibrosis
● Hypersensitivity pneumonitis
● Hypereosinophilic lung diseases
● Tracheobronchomalacia
● Pulmonary embolism
● Coronary Heart Failure
● Endobronchial tumor/foreign body
*Differential diagnostic conditions which commonly co-exist with
asthma are listed under co-morbidities in Table 2.
•Confirmed diagnosis of 
asthma?
•Poor asthma control?
•Asthma phenotype?
Diagnosis and 
phenotype?
•Optimal adherence ?
•Correct use of inhalers?
•Asthma education 
necessary?
Treatment
barriers?
•Exposures?
•Co-morbidities?Triggers?
Figure 2. Systematic assessment of possible severe asthma.
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(3) Serious exacerbations, defined as at least one
hospitalization, intensive care unit stay, or
mechanical ventilation in the previous year.
(4) Airflow limitation, defined as a forced expira-
tory volume in 1 s (FEV1) < 80% predicted (in
the presence of reduced FEV1/forced vital capa-
city (FVC) while withholding both short- and
long-acting bronchidilators.
d. The phenotype of asthma
Phenotyping severe asthma is important for predicting
treatment response. Phenotypes may be based on the
presence and level of inflammation, which may be
termed inflammatory phenotypes [16], or based on a
combination of clinical characteristics, physiological,
and inflammatory markers, which may be termed clin-
ical phenotypes [17–22].
Inflammatory phenotypes are ideally assessed by
induced sputum and divided into four groups: eosino-
philic asthma (>3% of the total sputum cells), neutro-
philic asthma (>61%), mixed granulocytic asthma
(both eosinophilia and neutrophilia), and pauci-granu-
locytic asthma (both eosinophil and neutrophil counts
in normal ranges) [23].
Blood eosinophils and exhaled nitric oxide (FeNO)
may be used as markers of eosinophilic airway inflam-
mation [24,25]: There is at present no consensus on the
most appropriate cut-off for blood eosinophils, but a
higher cut-off improves the predictive value of sputum
eosinophils: A cut-off of 0.30 x 109 cells/L yields a
positive predictive value (PPV) of 66%, which increases
to 89% at a cut-off of 0.45 x 109 cells/L [26]. However,
the increase in PPV is accompanied by a decrease in
sensitivity from 60% to 49% [26]. Similarly for FeNO, a
value > 50 ppb indicates a high likelihood of eosino-
philic airway inflammation, whereas a FeNO < 25 ppb
indicates a low likelihood of eosinophilia [25]. Many
patients have intermediate FeNO values (25–50ppb), in
these cases the FeNO is less informative. Of note,
neutrophilic airway inflammation can only be assessed
by induced sputum, as the level of blood neutrophils
does not accurately predict airway neutrophils [24].
At present, there is no clear consensus on the defi-
nition of clinical phenotypes of asthma [1]. However,
the ERS/ATS guidelines state that the following phe-
notypes of severe asthma are generally recognized: ‘an
early-onset allergic phenotype, a later onset obese (pri-
marily female) phenotype and a later onset eosinophilic
phenotype’ [1]. A systematic assessment should include
information on the following phenotypic characteris-
tics: a) age at onset (early/late); b) IgE-mediated allergy;
c) eosinophilia/elevated FeNO; d) fixed airflow
obstruction; and e) obesity.
From a pragmatic, clinical perspective, phenotypic
traits can be used in the daily clinical care to target-
specific treatments: eosinophilia combined with exacer-
bations predicts effect of anti-IL5 [27] and patients
with fixed airflow obstruction and exacerbations may
benefit from tiotropium [28]. Furthermore, perennial
allergic sensitization, airflow obstruction (FEV1 < 80%)
and exacerbations predict effect of anti-IgE [5].
Step 2. Treatment barriers (adherence, inhalation
technique, understanding of asthma)
Treatment barriers are factors that impede the ade-
quate delivery of asthma medications to the airways:
They are frequent causes of poor asthma control, and
should be addressed routinely in patients with severe
asthma. Unfortunately, adherence and inhalation tech-
nique are not routinely checked, and there appears to
be significant room for improvement: In a recent real
life study of patients managed for severe asthma,
adherence was only recorded in 30% of patients, and
inhalation technique in 19% [15].
a. Adherence with controller medication
Poor adherence in asthma is well-documented [29,30],
even in difficult asthma: A study of adults referred to a
clinic for difficult asthma revealed that 35% of the
patients filled their ICS prescriptions less than 50% of
the time [31]. Poor adherence with controller medica-
tion is associated with poor disease control, and it is
estimated that 24% of exacerbations and 60% of
asthma-related hospital admissions may be attributed
to poor adherence [29,32].
The high proportion of non-adherent patients poses
a major challenge for asthma specialists in identifying
patients suffering from severe asthma, that is asthma
not responding to high-dose medication. This may lead
to non-adherent patients inadvertently being pre-
scribed expensive biological medications [19].
Adherence with asthma controller medications
should therefore always be checked, preferably by
objective assessment, for example filling of prescrip-
tions in electronic registers.
b. Inhalation technique
Assessment of the individual patient’s inhaler techni-
que is important [33], and should be checked at each
visit [23].Errors in the use of inhalers are common
[34,35] and have previously been reported in up to
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80% of patients [33]. A further challenge in severe
asthma is that patients may be treated with two or
more different inhaler types, which may increase the
risk of errors. Also, the increasing number of inhala-
tion devices contributes to difficulties for health care
providers to have sufficient knowledge in the correct
method of use.
A comprehensive, inhaler specific checklist can be
downloaded at https://www.nationalasthma.org.au/liv
ing-with-asthma/resources/health-professionals/charts/
inhaler-technique-checklists.
c. Patient education
A shared-care approach to asthma management
improves outcomes [36,37], and requires development
of a partnership between the asthmatic and the health
care providers. Perhaps more than in other diseases
patients require good partnerships for adequate treat-
ment, they must learn to recognize potential triggers
and symptoms of exacerbations, when to adjust medi-
cations and contact health care personnel [13,38].
Step 3: Identifying potential triggers: exposures
and co-morbidities
a. Exposures
Identifying potential triggers causing potential asthma
symptoms and exacerbations is essential, and this sec-
tion describes exposures that should be identified as
part of the systematic assessment, including allergens,
smoking, occupational exposures and medications that
may aggravate symptoms.
Indoor allergens
Common indoor allergens that may trigger asthma
include pets—cats and dogs—house dust mite, moulds,
cockroaches, and rodents [39–41], and an important
part of the patients history includes asking about pos-
sible exposures to indoor allergens such as pets, carpet-
ing, and damp housing.
Outdoor allergens
Outdoor allergens such as pollen and mould spores can
trigger asthma exacerbations and increase asthma
severity in sensitized individuals. Exposure to fungi,
especially Alternaria and Cladosporium, have been
associated with an increase in asthma exacerbations
and asthma severity [42,43]. Pollen such as grass and
birch allergens induce primarily nasal and conjunctival
symptoms, but may also exacerbate asthma symp-
toms [44].
Tobacco smoke
Unfortunately, a large proportion of asthma patients
have a significant smoking history or are exposed to
passive smoking. Several lines of evidence demonstrate
that active and passive smoking leads to greater sever-
ity of asthma and act as a triggers to exacerbate asthma
[45,46]. It appears that the diminished antioxidant
capacity along with the oxidant excess associated with
tobacco smoke leads to bronchial hyperresponsiveness
and worsening airways obstruction [47,48] Due to the
accelerated loss of lung function, there is an increased
risk of development of COPD in asthmatics who
smoke (see ‘Co-morbidities’) [49]. However, it is also
important to recognize that smoking per se does not
preclude a diagnosis of asthma, and fixed airflow
obstruction in severe asthma is not synonymous with
COPD. Importantly, asthma patients who develop
COPD appear to have a better prognosis than COPD
patients without pre-existing asthma [50,51].
Occupational exposure
Exposure to multiple occupational allergens have been
associated with work-related asthma. These include
flour and grain dust (bakers, farmers), isocyanates
(painters, automotive industry workers, adhesive work-
ers), formaldehyde (health care workers, hairdressers,
cosmetic workers) wood dusts (carpenters) platinum
salts (dentists, chemists, photographers, electricians),
latex (health care workers, food handlers), and animal
allergens (veterinarians, animal breeders and workers,
laboratory workers) [52]. In patients with these occu-
pations, as well as patients who report worsening of
their symptoms at work, a referral to a specialist in
occupational medicine should be considered.
Drugs
Aspirin and other NSAIDs may trigger severe airway
obstruction in up to 10–15% of adults with asthma
[53–55]; typically patients with severe and adult onset
eosinophilic asthma and comorbid nasal polyposis, a
condition termed Samter´s triad, aspirin-exacerbated
respiratory disease (AERD) or Non-steroidal anti-
inflammatory drugs-exacerbated respiratory disease
(N-ERD) [56]. The intolerance is not an IgE mediated
allergy and there is no in vitro test for diagnosis.
β-receptor antagonists may trigger asthma and non-
selective systemic β-receptor antagonists should be
avoided in asthmatics. However, even the β1-selective
antagonists are not completely risk-free; 20% of
patients experience symptoms and airflow obstruction
after exposure, even to local β-receptor antagonists
such as eye drops [57,58].
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b. Co-morbidities associated with severe asthma
Co-morbidities are a common feature of severe asthma,
which may contribute to poor symptom control [59].
Conversely, co-morbidities may be caused by severe
asthma; steroid treatment is associated with an
increased risk of iatrogenic co-morbidities including
obesity, osteoporosis, diabetes, depression, and gastro-
intestinal reflux [1,60,61](Table 2).
The prevalence, diagnosis, and management of the
most common co-morbidities in severe asthma are
summarized in Table 1, and described in further detail
below:
Chronic rhinosinusitis (CRS)
Clinical studies have demonstrated that 50–90% of
subjects with severe asthma have signs of chronic rhi-
nosinusitis [62,63]. Patients with CRS may have co-
existing nasal polyps (CRSwNP), which is commonly
a feature of severe late-onset, eosinophilic asthma, and
may furthermore be associated with Aspirin/NSAID
sensitivity [56]. Patients with difficult asthma and
CRS report more lung symptoms, in particular more
cough and sputum, and have more exacerbations [62].
The presence of CRS is assessed on the basis of
clinical symptoms such as nasal discharge, in combina-
tion with facial pain/pressure or loss of smell, present
for a period of at least 12 weeks [64]. The SNOT-22
questionnaire may be used for assessing symptoms
[64], and CT of the sinuses and rhinoscopy may be
used to assess the presence of sinus inflammation and
polyposis [64].
Allergic rhinitis
Allergic rhinitis is common in asthma in general, and
seems to play a more important role in early onset
severe asthma, whereas in late-onset, severe asthma,
allergy generally seems to have less clinical impact [59].
COPD
Fixed airflow obstruction is a common feature of
severe asthma, and it may be impossible to differentiate
severe asthma from COPD, in patients with a signifi-
cant smoking history [65]. Additionally, a significant
proportion of severe asthma starts in adulthood, and
adult onset asthma in general is associated with low
lung function: As many as 46% of adults with asthma
onset after the age of 65 years have an FEV1 < 80%
prior to being diagnosed with asthma [66]. Hence,
asthma may precede COPD, or vice versa, and the
clinical impact of this order of development is as yet
unclear.
There is no gold standard for differentiating severe
asthma from COPD. The GINA guidelines on asthma-
COPD overlap syndrome suggest that the likelihood of
having either asthma or COPD is based on a thorough
assessment of smoking exposure, symptoms (e.g. vari-
able versus persistent symptoms, family history and
response to treatment) [67]. Additionally, assessing
components of emphysema, for example with DLCO
or HRCT may be helpful [50,68].
Dysfunctional breathing
Dysfunctional breathing (DB) may accompany asthma
or be an asthma mimicker. Defined as ‘chronic changes
in breathing pattern that result in dyspnoea and other
symptoms, in the absence or in excess of the magnitude
of physiological respiratory or cardiac disease’ [69], DB
is observed in up to 52% of subjects with difficult
asthma. DB seems to be most common in the obese
and non-eosinophilic phenotypes of severe asthma
[70,71]. Patients typically report very excessive dyspnea
at relatively low levels of physical activity, that is dys-
pnea that is disproportionate with the objective level of
asthma severity. Furthermore, extra-pulmonary com-
plaints such as dizziness, fatigue or tingling of the
fingers/around the mouth are common. There is no
gold standard for diagnosing DB, but patients may be
screened using the Nijmegen questionnaire, where a
score > 23 indicates an increased likelihood of DB [72].
Vocal cord dysfunction
Vocal cord dysfunction (VCD) is an important
mimicker of asthma: The vocal cords are inappropri-
ately adducted leading to a sense of dyspnea and short-
ness of breath with associated stridor rather than
wheezing [73]. VCD can present as a single disease
but in up to 50 % of patients concomitant VCD and
asthma are seen and may complicate diagnosis and
treatment in ‘treatment-resistant’ asthma [74]. The
diagnosis of VCD may be challenging, as laryngoscopy
may be normal when the subject is not experiencing
symptoms. No validated protocols for diagnosing VCD
exist, however provocation with stimuli such as per-
fume may be attempted. A typical symptom of VCD is
hoarseness during attacks. Patients may be screened for
VCD with the Pittsburgh questionnaire [75], and refer-
ral to a speech pathologist should be considered. VCD
may also be provoked by exercise. Continuous laryngo-
scopic exercise testing (CLE) may be performed to
visualize the larynx during exercise. CLE testing has
demonstrated that a large proportion of patients with
symptoms suggestive of VCD may demonstrate supra-
glottic closure of the aryepiglottic folds [76]. The term
Inducible Laryngeal Obstruction (ILO) has been
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proposed, to cover both glottic and supraglottic
obstruction, induced by stimuli such as exercise
(EILO) or external stimulants [76]. The relative preva-
lence of glottic (VCD) versus supraglottic obstruction
in severe asthma is unknown. CLE may be a useful test
for ILO in severe asthma, however protocols for valid-
ity and safety for this type of testing have yet to be
established.
Anxiety and depression
Anxiety and depression are prevalent conditions
among patients with severe asthma, and may contri-
bute to symptoms, but also be the result of having a
severe and chronic disease [77]. Patients may be
screened with questionnaires such as the Hospital
depression and Anxiety Scale (HADS) [78,79],
although there are as of yet no validated questionnaires
for asthma specifically. If anxiety or depression are
suspected, the patient should be referred for psychiatric
assessment at a center with experience in psychiatric
disorders in chronic disease.
Obstructive sleep apnea syndrome
Obstructive Sleep Apnea Syndrome (OSAS) is common
in severe asthma, and is associated with poor symptom
control and frequent exacerbations [80]. A potential
vicious cycle may result as OSAS may induce asthma
symptoms, and asthma increase the risk of OSAS [70].
Screening of patients for OSAS can be performed with
validated questionnaires such as the, STOP-BANG or
the Berlin Questionaire [81,82]. If OSAS is suspected,
patients should be referred for polysomnography [83].
Obesity
Overall, obesity is associated with worse asthma out-
comes, especially an increased risk of exacerbations
and asthma-related hospitalizations [68,84]. This data
may be confounded by other obesity related co-mor-
bidities which also affect asthma exacerbations such as
gastroesophageal reflux and sleep apnea [85].
Furthermore, obese asthmatics may have a lower
threshold for symptoms: A study comparing asthmatics
with higher levels of BMI (>31) compared with lean
asthmatics, found that the obese group had a 50%
increased risk of asthma exacerbations and a 94%
increase in use of rescue inhalers [86,87].
Gastroesophageal reflux disease (GERD)
GERD is associated with poor symptom control, as well
as more frequent exacerbations in severe asthma
[59,88]. Although the causal link is unclear, co-exis-
tence of gastroesophageal reflux is very common in
patients with asthma [89]. As the diagnosis of GERD
may be difficult, with limited sensitivity of both gastric
pH monitoring and endoscopy, a trial treatment with
PPI may be used as the initial diagnostic step in symp-
tomatic patients [90]. Of note, high use of beta2-agonist
has been shown to relax the sphincter between the
oesophagus and the ventricle, which increases the ten-
dency to reflux, potentially inducing a vicious cycle of
high SABA use, reflux and increasing asthma symp-
toms leading to high SABA use.
Bronchiectasis
The prevalence of bronchiectasis in patients with severe
asthma is relatively high; with 25–40% of patients having
radiological signs of bronchiectasis [91,92], compared to
3% in a population of generally milder asthma [93].
Asthma patients with co-existing bronchiectasis appear
to be at higher risk of asthma exacerbations and hospitali-
zations [93,94]. Bronchiectasis per semay cause obstructive
airflow limitation [92], and is thus a also a differential
diagnosis of asthma [95]. Furthermore, bronchiectasis
increases the susceptibility to infections [95].
Bronchiectasis is associated with allergic bronchopulmon-
ary aspergillosis (ABPA) in severe asthma [96], see below.
Allergic bronchopulmonary aspergillosis (ABPA)
ABPA is a hypersensitivity reaction to aspergillus fumi-
gatus [96]: Although a relatively rare condition, ABPA
may have significant impact on asthma control.
Typically patients experience symptoms of chronic
mucus hypersecretion and have an associated acceler-
ated loss of lung function [96].
The most recently diagnostic criteria for ABPA,
proposed by ISHAM (The international Society for
Human and Animal Mycology), in 2013 [97], are sum-
marized below:
Predisposing conditions
● Bronchial asthma, cystic fibrosis
Obligatory criteria (both should be present)
● Type I Aspergillus skin test positive (immediate
cutaneous hypersensitivity to Aspergillus antigen)
or elevated IgE levels against Aspergillus fumigatus.
● Elevated total IgE levels (> 1000 IU/mL) (If the
patient meets all other criteria, an IgE value <
1000 IU/mL may be acceptable).
Other criteria (at least two of three)
● Presence of precipitating or IgG antibodies
against A. fumigatus in serum.
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● Radiographic pulmonary opacities consistent with
ABPA (may be transient).
● Total eosinophil count > 500 cells/μL in steroid
naïve patients (may be historical).
Sensitization to aspergillus in severe asthma in the
absence of other features of ABPA has been termed
severe asthma with fungal sensitization (SAFS) [98].
The management of this condition is somewhat
debated: The ERS/ATS guidelines recommend that
severe asthma with fungal sensitization, without other
characteristics of ABPA, should not be treated with
anti-fungal agents, due to an overall negative risk-ben-
efit ratio associated with anti-fungal agents [1].
Management of severe asthma
a. Non-pharmacological treatments
Asthma education
Educating patients in self-management improves
health outcomes in severe asthma [8]: Key compo-
nents of teaching self-management are ensuring
adequate knowledge about asthma, providing writ-
ten action plans, teaching correct inhalation techni-
ques, and encouraging adherence with medications
[8]. As doctors often have limited time for the
individual patient, specialized asthma nurses may
have an important role in providing self-manage-
ment education.
Written action plans
Individualized asthma action plans have been demon-
strated to improve quality of life [99] and reduce hos-
pital admissions in patients with severe disease. The
action plan should include both guidance on mainte-
nance therapy, as well as advice on how to recognize
and manage exacerbations [37].
Inhaler technique
Many patients with asthma (up to 70–80%) are unable
to use their inhaler(s) correctly [13]. Poor inhaler tech-
nique leads to reduced asthma control, increased risk
of exacerbations and increased adverse effects [33]. Key
components ensuring correct inhalation technique are:
choosing the most optimal device for the individual
patient, avoid different inhaler types when possible
and physically demonstrating the use of the inhaler
with a placebo inhaler. Furthermore, check inhalation
technique with a device-specific checklist on a regular
basis, as errors often recur [13].
Improving adherence
The first step in improving adherence is to identify the
cause of poor adherence, before deciding on an inter-
vention: Intentional non-adherence because of fear of
side effects or perception that a treatment is unnecessary,
or non-intentional non-adherence, due to forgetfulness or
misunderstanding of instructions, or because of the cost
of medications. Finally, some patients have difficulty in
being adherent due to difficulties using the device, or
because of a regimen with multiple inhalers is over-
whelming [13]. Patients with intentional non-adherence
due to side effects may need an empathic discussion
about the pros and cons of their treatment [36], whereas
patients with non-intentional adherence due to forgetful-
ness may need a more feasible regimen such as once-
daily dosing [100], and inhaler reminders [101,102].
Removing allergens
In general, allergen avoidance is not recommended as a
treatment for asthma. Studies on asthma patients that
are sensitized to house dust mite and/or pets, show
limited evidence of clinical benefit for asthma with
multi-component avoidance and there are no validated
methods for identifying those who are likely to benefit
[103]. However, in subjects with symptomatic allergy,
allergen specific avoidance should be considered if
feasible (e.g. removal of furred pets in those with spe-
cific sensitization).
In addition, some studies have shown that remediat-
ing dampness or mould damages in houses and offices
result in reduction of asthma related symptoms and
medication use in adults [104].
Another potential method for reducing allergen expo-
sure in for severe allergic asthma, which needs further
study, is Temperature-controlled Laminar Airflow (TLA).
This treatment is given with a device (Airsonette) that is
placed at the patient’s bed and creates an allergy free zone
around the patient face in bed, by filtering and lowering
the temperature. This treatment has been shown to
reduce airway inflammation, and improve quality of life
in patients with uncontrolled allergic asthma [105], but
has yet to be studied in severe asthma.
Smoking cessation
Smoking cessation improves bronchial hyperrespon-
siveness, as well as symptom control [106], and should
be encouraged in all asthma patients.
b. Pharmacological treatments
This part of the guidelines are mostly based on the
GINA guidelines [107] with some modifications
(Figure 3)
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Step 4 treatment
The pharmacological treatment step 4 is based on
medium to high doses of inhaled corticosteroids (ICS)
(Figure 3). Patients with severe asthma are per defini-
tion treated with high dose ICS (Table 1), combined
with a second controller, with inhaled long acting beta-
2-agonists (LABA) being the first choice. Other second
controllers include leukotriene receptor antagonists
(LTRA) [108], tiotropium or theophylline, possibly in
combination. The effect of adding in tiotropium is
possibly better in ex-smokers than never-smokers
[109]. For reliever treatment, short-acting beta-agonists
or ICS in combination with formoterol are the two
alternatives. In patients with repeated exacerbations
using ICS+formoterol is preferred [110]
Step 5 treatment
When adequate asthma control with the above treat-
ment is not achieved, oral corticosteroids (OCS) may
be added [107], although the evidence for efficacy of
long-term OCS in severe asthma is weak. Importantly,
the OCS should be used in as low a dose and for the
briefest period possible because of the risk of systemic
side effects such as osteoporosis [111].
Allergic asthma
Anti-IgE treatment with omalizumab, a well-studied
humanized recombinant IgG1 monoclonal antibody
with multiple mechanisms of action beyond binding
free IgE [112], is an option in severe asthmatics with
confirmed perennial allergies (pets or mites). In
patients with severe allergic asthma, the add-on treat-
ment with omalizumab has been shown to reduce the
risk of exacerbations [113–117], the asthma symptoms
[113,114,116,118], and the use of OCS [118] and ICS
[115], as well as to improve the quality of life and lung
function [113,114,116], without significant safety con-
cerns. These beneficial effects of omalizumab first
shown in randomized clinical trials have been con-
firmed in longer term real-life studies [119–121], and
appear to be independent on patients’ comorbid-
ities [118].
Immunotherapy (IT) is presently not recommended
in uncontrolled asthma. While in patients with less
severe asthma (FEV1 > 70% pred.), HDM-SLIT effec-
tively decreased the number of exacerbations [Virchow
JC, et al JAMA 2016], resulting in the inclusion of
HDM SLIT in GINA 2017, so far AIT has not been
evaluated in severe asthma and hence is an unmet
need. The safety of immunotherapy may be improved
with addition of Omalizumab [122]. The combined use
of Omalizumab followed by IT represents an interest-
ing potential management strategy in severe allergic
asthma, and further studies are urgently needed.
Eosinophilic asthma
Treatment with anti-IL5 has been shown to decrease
the risk of exacerbations in patients with eosinophilic
asthma [123]. Two compounds are available: mepoli-
zumab which is given subcutaneously and reslizumab
which is given intravenously. Both drugs are adminis-
tered every 4 weeks. In addition to reducing asthma
exacerbations, reslizumab has been shown to increase
lung function and improve symptom control [124].
Studies indicate an increased effect of anti-IL5 the
higher the eosinophilia. [123]. Anti-IL-5 is not indi-
cated unless eosinophil levels are 0.3 x 109/L or greater.
The cost of anti-IL-5 is similar to that of omalizumab.
Recent results from the AMAZES study suggest, that
low-dose long-term macrolide treatment may improve
SABA SABA or ICS + formoterol
Medium-high dose ICS initially
or in periods
Low dose ICS
Low dose
ICS + 
LTRA
+LTRA
+LAMA
+OCS
Low dose
ICS + 
LABA
Medium-
high dose
ICS +LABA
ICS+
LABA+
LTRA
+Anti IgE
or
+ Anti-IL5
or
+Macro-
lides
(Phenotype
dependent)
Preferred controller
treatment
Other
controller
options
Reliever
Step 1
Step 2
Step 4
Step 3
Step 5
SABA: Short acting β2 agonists
ICS: Inhaled corticosteroids
LABA: Long acting β2 agonists
LAMA: Long acting anti-cholinergics
LTRA:  Leukotriene receptor antagonsts
OCS: Oral corticosteroids
Figure 3. Treatment steps according to GINA guidelines on asthma (REF).
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asthma control in eosinophilic asthma, as well as non-
eosinophilic asthma (see below) [125]
Non-eosinophilic asthma
Macrolides are normally used as antibiotics, but these
compounds also have airway biofilm-modifying and
anti-inflammatory effects. Treatment with a low dose
azithromycin: 250 mg 3 days per week have been
shown to reduce the risk of exacerbations in patients
with non-eosinophilic asthma (B-Eos≤ 0.2 x 109/L)
[126]. In the recently published AMAZES study, low-
dose Azithromycin (500 mg 3 days/week for 48 weeks),
in addition to usual treatment, reduced exacerbations
in uncontrolled eosinophilic as well as non-eosinophi-
lic asthma, as well as asthma-related quality of life
[125]. Macrolides reduce neutrophilic airway inflam-
mation [127], but further mechanistic studies are
required to understand the mechanisms of action in
eosinophilic asthma.
Roflumilast is a phosphodiesterase-4 inhibitor. It
is used in severe COPD especially if the patient also
has chronic bronchitis. There are some data suggest-
ing a beneficial effect of roflumilast in severe
asthma [128].
Bronchial thermoplasty (BT)
In BT, localized radiofrequency pulses are applied to
the airways with bronchoscopy. The treatment has
been shown to reduce the risk of asthma exacerbations
[129], but is associated with a risk of severe exacerba-
tions in relation to the three bronchoscopies required.
Moderate and severe bronchiectasis, very high sputum
production, and fixed airflow obstruction with FEV1
levels below 50% predicted are important contraindica-
tions for BT. The mechanisms underlying the potential
effects of BT are unclear, and may involve effects on
the neural innervation of the airways, or on the
immune response, as well as the direct effect on airway
smooth muscles [130]. Importantly, here is an urgent
need for studies that clarify the effect of BT in specific
phenotypes of severe asthma, in order to inform clin-
icians on how to identify patients that will benefit
from BT.
c. Management of co-morbidities
Management of co-morbidities is important, as they
may contribute to the severity of asthma [131]. In
general, there is a relative paucity of data on the effect
of co-morbidities in asthma .
Chronic rhinosinusitis (CRS), nasal polyposis
Nasal steroids, systemic steroid treatment, antibiotics,
functional endoscopic sinus surgery and aggressive
nasal lavage are recommended for the treatment of
CRS [64] and improve nasal symptoms. Whereas both
medical and surgical interventions have been shown to
improve nasal outcomes, there are not convincing data
to suggest an improvement in asthma-related outcomes.
In patients with CRS and concomitant nasal polyps
(CRSwNP), functional endoscopic surgery (FESS) may
reduce asthma symptoms [132], however polyps tend
to relapse [133]. Nasal polyps in severe asthma are
predominantly eosinophilic, and treatment with anti-
IL5 may be a future treatment option [134].
Allergic rhinitis
Patients with allergic rhinitis and severe asthma are
treated with antihistamines, nasal steroids, saline irri-
gation and specific allergen immunotherapy [135].
Furthermore, anti-leukotrienes may target both upper
and lower airways [135,136].
In patients with severe asthma and perennial aller-
gies, anti-IgE (omalizumab) may reduce exacerbation
rates [118,137]: Patients with symptoms of allergic
rhinitis are more likely to benefit from omalizumab
with a substantial reduction in symptoms of rhinitis,
as well as those of asthma [138].
COPD
Little evidence exists on the outcomes of specific treat-
ments in patients with co-existing severe asthma and
COPD. However, a multidimensional approach, where
treatable traits are identified and targeted is being
suggested [139]. This includes addition of LAMA in
patients with fixed airflow obstruction, PDE4 inhibitors
in patients with significant sputum production and
exacerbations, smoking cessation programs, and pul-
monary rehabilitation in patients with exertional dys-
pnea [119].
Dysfunctional breathing
Breathing retraining may improve symptom control in
asthma in general [140], although the effect in severe
asthma has not yet been examined. Different protocols
for breathing retraining exist, but the general principle
is to teach the patient to breathe slowly, through the
nose and diaphragmatic breathing instead of using
auxiliary respiratory muscles and the apical part of
their chest [140,141]. Breathing retraining is performed
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by physiotherapists and may be combined with relaxa-
tion techniques. As these techniques are not performed
by all physiotherapists, specific training of local staff
may be required.
Vocal cord dysfunction
VCD may be treated with speech therapy, intended to
instruct patients how to relax their vocal cords [142].
The effect of speech therapy has not been studied
specifically in severe asthma, but may be attempted in
individual patients.
Anxiety and depression
Psycho-educational interventions such as cognitive
behavioural therapy and relaxation techniques may
improve asthma control and reduce exacerbations
[143], although the evidence is based on small and
heterogeneous studies. Access to a psychologist with
experience in managing patients with chronic disorders
may be helpful in the management of severe
asthma [8].
Obesity
Weight reduction has been shown to improve both
symptom control, lung function, and airway hyperre-
sponsiveness in obese asthma patients [144–146]. Even
a moderate weight loss of 5–10% is sufficient to achieve
clinical improvements [147]. Therefore, obese asthma
patients are recommended to lose weight, possibly with
the aid of a dietician. Bariatric surgery may be consid-
ered in some cases.
Obstructive sleep apnea (OSAS)
Although the effect has not been studied in difficult
asthma per se, CPAP treatment may improve symptom
control, lung function, as well as decrease exacerbation
rates [148] and airway hyperresponsiveness in asthma
in general [149].
Gastro-esophageal reflux (GERD)
The effect of treating GERD in severe asthma is uncer-
tain: Whereas some studies have demonstrated an
effect on symptoms, quality of life and exacerbations,
no convincing effect has been demonstrated on lung
function and airway hyperresponsiveness [90,150].
Hence, PPI treatment may be considered in the indivi-
dual patient.
Bronchiectasis
Management of bronchiectasis aims at improving air-
way clearance. This can be achieved by reducing air-
ways inflammation, inhalation of hyperosmolar agents
and by pulmonary physiotherapy and exercise [151].
Low-dose macrolide treatment may reduce exacer-
bations in patients with bronchiectasis [151,152].
However, the effect of treating bronchiectasis in severe
asthma has not been investigated, and there is a need
for further studies.
Allergic bronchopulmonary aspergillosis
Management of ABPA aims to reduce airway inflamma-
tion. This includes treatment with systemic corticoster-
oids, typically given over months, with an initial dose of
0.5mg/kg of prednisone, tapered over 6–8 weeks, but
sometimes over longer periods [96]. Anti-fungal agents
may be given in combination with corticosteroids.
Itraconazole (200 mg twice daily) is the recommended
choice, but voriconazole and posaconazole have also
shown a clinical effect in ABPA [96]. Anti-IgE treatment
has been shown to be effective in ABPA patients [153]
and may be considered in individual patients.
Organization of a severe asthma clinic
The assessment of difficult asthma should be done by
using a systematic approach [1,4,8] in a specialist cen-
ter, as this leads to better treatment outcomes and saves
costs [2,154,155]. Systematic assessment is also impor-
tant in ensuring that novel expensive treatments are
only used in patients likely to respond. Unfortunately
only a minority of subjects considered having severe
asthma have been systematically assessed [9]. There are
no studies formally assessing the best way to organize
the management of severe asthma, but based on cur-
rent understanding and recommendations by other
societies [103] we recommend the following.
Recommendations for a severe asthma center
A severe asthma center is a specialized unit devoted to
diagnosing and the management of severe asthma.
Depending on the structure of the health care system it
can be organized as a single administrative unit or as
collaborative network between professionals from differ-
ent units. The key elements of a severe asthma center are:
● Severe asthma is the main focus of the center.
● Systematic assessment is used in the diagnostic
work-up of severe asthma.
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● Several disciplines are represented and a multidis-
ciplinary team is involved in patient management.
● Good facilities for diagnostics and differential
diagnostics are available as well as a broad spec-
trum of treatment modalities.
● The personnel is devoted in continuously improv-
ing management of severe asthma and the center
is in collaboration with other centers nationally
and internationally.
● Clinical research in severe asthma is part of the
centers everyday practice and register data are
collected to help facilitate research, administra-
tion, and assessment of expensive treatments.
● The center(s) coordinate the management of
severe asthma and are responsible for education
of other health care personnel in the area.
We recommend that a severe asthma center should
have the following professionals working within the
center or in close collaboration:
● Pulmonologist/allergist and clinical immunolo-
gists (preferably at least two persons) specialized
in severe asthma and dedicated to lead and
develop the center.
● ENT specialists with an interest in rhinology and
laryngeal diseases.
○ preferably also a speech pathologist/laryngologist
● Specialist asthma nurse.
● Physiotherapist specialized in dysfunctional
breathing and abnormal breathing patterns, cap-
able of assessing and educating patients.
● Radiologist, preferably specialized in thoracic
radiology.
● Dietician.
● Psychologist.
Regular Multidisciplinary team (MDT) conferences are
useful to ensure an effective decision process in the man-
agement of the individual patient. Entering the informa-
tion gathered during the systematic assessment into a
standardized summary sheet may be helpful to ensure
an overview during and after the MDT, and might be
used in addition as a discharge summary for patients
attending the clinic and are referred back locally.
Examples are shown in the online supplementum.
We recommend that a severe asthma center should
have the following equipment/methods available in
addition to normal hospital facilities:
● Lung function measurements (spirometry, dif-
fusing capacity, body plethysmography, meth-
ods to test for bronchial hyperreactivity (e.g.
methacholine, histamine, mannitol), exercise
challenges or spiroergometry, impulse oscillo-
metry or forced oscillometry.
● Allergy testing with skin prick testing or serum
level of allergen specific IgE and allergen chal-
lenge testing.
● Blood tests available, including blood eosinophil
counts.
● Tests for airway inflammation: FeNO and prefer-
entially also induced sputum.
● Tests for immunological diseases and/or a clinical
immunologist available.
● Bronchoscopy.
● Rhinoscopy.
● Laryngoscopy, which can be performed at rest and
during exercise.
● High resolution computed tomography of chest
and sinus CT.
● Polysomnography/respiratory polygraphy.
Organizing severe asthma treatment at national level
In areas where population density is high and long dis-
tances are not amajor problem, the evaluation and care of
severe asthma is usually best organized by establishing
several severe asthma centers that take care of their own
area. In areas with low population density and large
geographical distances, where establishing a true severe
asthma center may not be possible, we propose that
severe asthma teams may be helpful in improving the
treatment of severe asthma. A severe asthma team could
be based in local respiratory clinics or other health care
units. Such a team would require 1–2 respiratory specia-
lists devoted to severe asthma as well as 1–3 nurses also
specialized in severe asthma. It is important that severe
asthma teams are devoted to the systematic assessment of
severe asthma, interdisciplinary collaboration, and other
key elements paralleling a true severe asthma center as
much as possible. A severe asthma team should be in
close collaboration with the severe asthma center respon-
sible for the area and subjects treated by the team would
be included in the register data of the local severe asthma
center. Initiation of expensive treatments may be decided
by referral to the local severe asthma center or by
consultations.
Referral requirements
The organization of asthma care differs among Nordic
countries. In most countries the majority of adult asth-
matics are diagnosed and treated in primary health
care. However, a patient with a suspicion of or proven
severe asthma should be referred to the local severe
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asthma center or team. As the number of patients with
adult and/or adult-onset asthma is high and the burden
from these patients is high [156], we propose a two-
step model, where the generalist may initially refer the
patient to a respiratory specialist, if there is a strong
suspicion of or a proven severe asthma, the patient is
subsequently referred to the severe asthma center/team
(Figure 4). However, depending on the local situation,
direct referral from the GP office to the severe asthma
center or team may be preferable . A summary of the
information that a referral letter to a severe asthma
center should include is shown in Box 2.
Future directions
The principle target in severe asthma is to achieve
optimal control while avoiding side-effects. Reaching
this goal is a challenge. However recent advances
enabling a better understanding of the mechanisms
that drive this disease is changing our approach to
how we approach the severe asthmatic, both with
regards to diagnosis and treatment. In this context
advanced phenotyping and endotyping are crucial
[157,158]. This includes collecting clinical information
on the individual patient as well as laboratory data such
as biomarkers to identify endotypes that underlie phe-
notypes and make tailored therapy possible [159,160].
Data from both randomized controlled trials [161]
(with wide inclusion criteria, followed by subgroup
analyses to identify the responder subpopulations
[162]), as well as real world evidence should be incor-
porated [163]. Importantly, the major advances in the
management of severe asthma are associated with phe-
notypes of Type 2-high asthma (e.g. atopic and eosi-
nophilic phenotypes) [163,164], whereas both
predictive biomarkers and treatments for asthmatics,
whose disease does not show presence of the type 2
inflammation are very limited. Furthermore, it is
important to mention that the phenotyping, endotyp-
ing, and selecting biomarkers for the personalized
approach do not necessarily include single biomole-
cules, but rather be composed of properly selected
constellations or signatures of proteins and other pep-
tides, transcriptomes, genes, microRNAs [164] and
metabolites [165,166]. Finally, there is a need for
more evidence on the consistency of severe asthma
phenotypes, throughout the clinical course of severe
asthma [23,159,163,167–169].
Other important issues to be solved regarding severe
asthma include gathering information on the
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Figure 4. A model for organization of severe asthma management.
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prevalence and burden of severe asthma in different
countries and regions, where in many cases the data are
scarce or absent [170]. Moreover, little is know about
the impact of local and socio-cultural factors on the
diagnosis and treatment of severe asthma and how this
may impact the possibilities to utilize add-on and novel
personalized therapies to improve the outcomes in
each area [170]. Barriers associated with cost of med-
ication and approval/reimbursement of expensive
therapies are an additional challenge and add to this
complexity. [170]. Further cost-effectiveness analyses
are necessary.
The biological (e.g. anti-IL-5 and anti-IgE antibodies)
and other specialized (e.g. bronchial thermoplasty) treat-
ments are expensive. The costs are another factor limiting
the number of patients being offered these therapies.
National differences in these expensive treatments may
differ due to different funding strategies between coun-
tries. This undermines the need for international guide-
lines facilitating the selection of subjects most likely to
respond the these novel treatments . On a national level,
local severe asthma centers in collaboration with the
authorities should provide a list of appropriate criteria
for selection of patients to receive novel biological treat-
ments in the respective countries. The decision to initiate
these treatments should then be made at the severe
asthma centers after amultidisciplinary systematic assess-
ment process, and the efficacy of the treatment should be
monitored systematically, to ensure that the treatment is
effective and was targeted to the appropriate patients.
Finally, national registers of patients treated with expen-
sive biologicals will be important in ensuring evidence on
the ‘real-life’ use and efficacy of these drugs.
In conclusion, severe asthma is a difficult clinical
challenge, which requires highly specialized care. The
development of novel biological treatments, which are
expensive, and only effective in selected groups of
patients, has further necessitated a high level of exper-
tise among specialists. Local centers for the diagnosis
and management of severe asthma are important in
achieving these goals.
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